| Active ingredients | Dosage form | Quantity of active ingredients | Shortage status | Availability | Reason | Last updated |
| tramadol hydrochloride | Tablet, modified release | 200 mg | Current | Limited Availability | Manufacturing | 13/12/2024 |
| tadalafil | Tablet, film coated | 20 mg | Current | Limited Availability | Manufacturing | 13/12/2024 |
| entecavir | Tablet, film coated | .5 mg | Current | Limited Availability | Manufacturing | 13/12/2024 |
| prilocaine hydrochloride~felypressin | Injection, solution | 30 mg/mL~.54 microgram/mL | Anticipated | Available | Manufacturing | 13/12/2024 |
| tranexamic acid | Injection, solution | 1000 mg | Current | Limited Availability | Commercial Changes / Commercial viability | 13/12/2024 |
| morphine hydrochloride trihydrate | Injection, solution | 20 mg/mL | Anticipated | Available | Manufacturing | 13/12/2024 |
| ramucirumab | Injection, intravenous infusion | 100 mg | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 13/12/2024 |
| codeine phosphate hemihydrate~ibuprofen | Tablet, film coated | 12.8 mg~200 mg | Anticipated | Available | Transport / Logistic issues / Storage capacity issues | 13/12/2024 |
| esomeprazole | Capsule, enteric | 20 mg | Anticipated | Available | Manufacturing | 13/12/2024 |
| encorafenib | Capsule, hard | 75 mg | Current | Limited Availability | Manufacturing | 13/12/2024 |
| atorvastatin calcium trihydrate | Tablet, film coated | 86.751 mg | Anticipated | Available | Manufacturing | 13/12/2024 |
| atorvastatin calcium trihydrate | Tablet, film coated | 43.376 mg | Anticipated | Available | Manufacturing | 13/12/2024 |
| pegcetacoplan | Injection, solution | 1080 mg | Current | Limited Availability | Manufacturing | 13/12/2024 |
| rifabutin | Capsule, hard | 150 mg | Current | Limited Availability | Transport / Logistic issues / Storage capacity issues | 13/12/2024 |
| doxycycline hyclate | Tablet, film coated | 57.5 mg | Anticipated | Available | Manufacturing | 13/12/2024 |
| olanzapine | Injection, powder for | 10 mg | Current | Limited Availability | Unexpected increase in consumer demand | 13/12/2024 |
| moclobemide | Tablet, film coated | 150 mg | Current | Limited Availability | Manufacturing | 13/12/2024 |
| acetylcholine chloride | Solution, powder for irrigation | 10 mg/mL | Current | Unavailable | Manufacturing | 12/12/2024 |
| ramipril | Capsule, hard | 1.25 mg | Current | Limited Availability | Manufacturing | 12/12/2024 |
| ibuprofen~codeine phosphate hemihydrate | Tablet, film coated | 200 mg~12.8 mg | Discontinued | Unavailable | Transport / Logistic issues / Storage capacity issues | 12/12/2024 |
| mirtazapine | Tablet, film coated | 45 mg | Current | Limited Availability | Manufacturing | 12/12/2024 |
| Somatropin | Injection, powder for | 12 mg/mL | Resolved | Available | Transport / Logistic issues / Storage capacity issues | 12/12/2024 |
| risperidone | Tablet, film coated | 1 mg | Current | Limited Availability | Unexpected increase in consumer demand | 12/12/2024 |
| duloxetine hydrochloride | Capsule, enteric | 67.32 mg | Current | Unavailable | Commercial Changes / Commercial viability | 12/12/2024 |
| drospirenone~ethinylestradiol | Tablet, film coated | 3 mg~.03 mg | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 12/12/2024 |
| clonazepam | Tablet, uncoated | .5 mg | Current | Limited Availability | Unexpected increase in demand due to other sponsors unable to supply | 12/12/2024 |
| dosulepin (dothiepin) hydrochloride | Capsule, hard | 25 mg | Current | Unavailable | Manufacturing | 12/12/2024 |
| daptomycin | Injection, powder for | 500 mg | Discontinued | Unavailable | Commercial Changes / Commercial viability | 12/12/2024 |
| tamoxifen citrate | Tablet | 30.34 mg | Current | Limited Availability | Manufacturing | 12/12/2024 |
| sitagliptin hydrochloride monohydrate~metformin hydrochloride | Tablet, modified release | 113.37 mg~1000 mg | Current | Unavailable | Manufacturing | 12/12/2024 |
| tamoxifen citrate | Tablet, uncoated | 15.2 mg | Anticipated | Available | Manufacturing | 12/12/2024 |
| prazosin hydrochloride | Tablet, uncoated | 1.1 mg | Current | Unavailable | Manufacturing | 12/12/2024 |
| prazosin hydrochloride | Tablet, uncoated | 2.2 mg | Current | Unavailable | Manufacturing | 12/12/2024 |
| prazosin hydrochloride | Tablet, uncoated | 5.5 mg | Current | Unavailable | Manufacturing | 12/12/2024 |
| nizatidine | Capsule | 300 mg | Current | Limited Availability | Manufacturing | 12/12/2024 |
| nizatidine | Capsule, hard | 300 mg | Anticipated | Available | Manufacturing | 12/12/2024 |
| flecainide acetate | Injection, solution | 10 mg/mL | Current | Unavailable | Manufacturing | 11/12/2024 |
| methylphenidate hydrochloride | Tablet, modified release | 27 mg | Anticipated | Available | Manufacturing | 11/12/2024 |
| fentanyl | Drug delivery system, transdermal | 8.4 mg | Anticipated | Available | Unexpected increase in demand due to other sponsors unable to supply | 11/12/2024 |
| gabapentin | Tablet, film coated | 600 mg | Resolved | Available | Manufacturing | 11/12/2024 |
| azithromycin dihydrate | Tablet, film coated | 524.1 mg | Resolved | Available | Unexpected increase in demand due to other sponsors unable to supply | 11/12/2024 |
| oxytocin | Injection, solution | 10 IU | Current | Unavailable | Manufacturing | 11/12/2024 |
| cisatracurium besilate | Injection, solution | 13.4 mg | Discontinued | Unavailable | Commercial Changes / Commercial viability | 11/12/2024 |
| simvastatin | Tablet, film coated | 10 mg | Current | Limited Availability | Manufacturing | 11/12/2024 |
| simvastatin | Tablet, film coated | 80 mg | Anticipated | Available | Manufacturing | 11/12/2024 |
| morphine hydrochloride trihydrate | Injection, solution | 10 mg/mL | Anticipated | Available | Manufacturing | 11/12/2024 |
| tenofovir disoproxil maleate | Tablet, film coated | 300 mg | Current | Limited Availability | Manufacturing | 11/12/2024 |
| ezetimibe | Tablet, uncoated | 10 mg | Current | Limited Availability | Unexpected increase in consumer demand | 11/12/2024 |
| nicotinic acid | Tablet, uncoated | 250 mg | Current | Unavailable | Manufacturing | 11/12/2024 |
| ivabradine hydrochloride | Tablet, film coated | 8.085 mg | Anticipated | Available | Manufacturing | 11/12/2024 |
| ezetimibe~atorvastatin calcium trihydrate | Tablet, film coated | 10 mg~20.681 mg | Current | Unavailable | Manufacturing | 11/12/2024 |
| dexmedetomidine hydrochloride | Injection, concentrated | 118 microgram/mL | Current | Limited Availability | Manufacturing | 11/12/2024 |
| naloxone hydrochloride dihydrate | Spray, nasal | 2.2 mg/actuation | Current | Limited Availability | Manufacturing | 11/12/2024 |
| aciclovir | Injection, solution | 25 mg/mL | Resolved | Available | Unexpected increase in demand due to other sponsors unable to supply | 11/12/2024 |
| aciclovir | Injection, solution | 25 mg/mL | Resolved | Available | Manufacturing | 11/12/2024 |
| temozolomide | Capsule, hard | 5 mg | Resolved | Available | Manufacturing | 11/12/2024 |
| methylphenidate hydrochloride | Tablet, modified release | 54 mg | Current | Limited Availability | Unexpected increase in demand due to other sponsors unable to supply | 11/12/2024 |
| methylphenidate hydrochloride | Tablet, modified release | 18 mg | Current | Limited Availability | Unexpected increase in demand due to other sponsors unable to supply | 11/12/2024 |
| levothyroxine sodium | Tablet, uncoated | .2 mg | Current | Limited Availability | Manufacturing | 11/12/2024 |
| tirzepatide | Injection, solution | 5 mg | Current | Unavailable | Commercial Changes / Commercial viability | 11/12/2024 |
| metformin hydrochloride | Tablet, film coated | 850 mg | Current | Unavailable | Manufacturing | 11/12/2024 |
| metformin hydrochloride | Tablet, film coated | 1000 mg | Current | Unavailable | Manufacturing | 11/12/2024 |
| methylphenidate hydrochloride | Tablet, modified release | 36 mg | Anticipated | Available | Manufacturing | 11/12/2024 |
| lidocaine hydrochloride monohydrate~adrenaline (epinephrine) acid tartrate | Injection, solution | 21.3 mg/mL~22.7 microgram/mL | Anticipated | Available | Manufacturing | 10/12/2024 |
| hydrocortisone acetate | Eye Ointment | 10 mg/g | Current | Unavailable | Manufacturing | 10/12/2024 |
| morphine hydrochloride trihydrate | Oral Liquid, solution | 5 mg/mL | Resolved | Available | Commercial Changes / Commercial viability | 10/12/2024 |
| losartan potassium | Tablet, film coated | 50 mg | Current | Limited Availability | Manufacturing | 10/12/2024 |
| losartan potassium | Tablet, film coated | 25 mg | Current | Limited Availability | Manufacturing | 10/12/2024 |
| heparin sodium | Injection, solution | 25000 IU/mL | Anticipated | Available | Manufacturing | 10/12/2024 |
| duloxetine hydrochloride | Capsule, enteric | 33.65 mg | Discontinued | Unavailable | Manufacturing | 10/12/2024 |
| duloxetine hydrochloride | Capsule, enteric | 67.3 mg | Discontinued | Unavailable | Manufacturing | 10/12/2024 |
| duloxetine hydrochloride | Capsule, enteric | 33.66 mg | Current | Unavailable | Unexpected increase in consumer demand | 10/12/2024 |
| efmoroctocog alfa | Injection, powder for | 250 IU | Current | Unavailable | Unexpected increase in consumer demand | 10/12/2024 |
| candesartan cilexetil | Tablet, uncoated | 4 mg | Current | Limited Availability | Manufacturing | 10/12/2024 |
| tranexamic acid | Injection, solution | 100 mg/mL | Current | Limited Availability | Manufacturing | 10/12/2024 |
| azithromycin dihydrate | Tablet, film coated | 524 mg | Current | Limited Availability | Manufacturing | 10/12/2024 |
| nizatidine | Capsule, hard | 150 mg | Current | Unavailable | Manufacturing | 10/12/2024 |
| atorvastatin calcium trihydrate | Tablet, film coated | 86.76 mg | Current | Limited Availability | Manufacturing | 10/12/2024 |
| tenofovir disoproxil fumarate | Tablet | 300 mg | Resolved | Available | Manufacturing | 10/12/2024 |
| levetiracetam | Tablet, film coated | 1000 mg | Resolved | Available | Manufacturing | 10/12/2024 |
| nebivolol hydrochloride | Tablet | 5.45 mg | Resolved | Available | Manufacturing | 10/12/2024 |
| trimethoprim | Tablet, uncoated | 300 mg | Current | Limited Availability | Manufacturing | 10/12/2024 |
| sitagliptin fumarate | Tablet, film coated | 32.124 mg | Current | Unavailable | Manufacturing | 10/12/2024 |
| olmesartan medoxomil~amlodipine besilate | Tablet, film coated | 40 mg~13.88 mg | Current | Unavailable | Manufacturing | 10/12/2024 |
| methylphenidate hydrochloride | Tablet, modified release | 36 mg | Anticipated | Available | Unexpected increase in demand due to other sponsors unable to supply | 10/12/2024 |
| methylphenidate hydrochloride | Tablet, modified release | 27 mg | Anticipated | Available | Unexpected increase in demand due to other sponsors unable to supply | 10/12/2024 |
| melatonin | Capsule, hard | 5 mg | Current | Limited Availability | Unexpected increase in consumer demand | 10/12/2024 |
| melatonin | Oral Liquid, solution | 1 mg/mL | Current | Limited Availability | Unexpected increase in consumer demand | 10/12/2024 |
| fosinopril sodium | Tablet, uncoated | 10 mg | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 10/12/2024 |
| droperidol | Injection, solution | 2.5 mg/mL | Discontinued | Unavailable | Commercial Changes / Commercial viability | 10/12/2024 |
| albendazole | Tablet, chewable | 200 mg | Current | Unavailable | Manufacturing | 10/12/2024 |
| cisatracurium besilate | Injection, solution | 6.7 mg/mL | Current | Unavailable | Manufacturing | 10/12/2024 |
| azithromycin dihydrate | Tablet, film coated | 628.93 mg | Current | Unavailable | Manufacturing | 10/12/2024 |
| norethisterone acetate~estradiol | Drug delivery system, transdermal | 2.7 mg~.62 mg | Current | Limited Availability | Manufacturing | 10/12/2024 |
| adrenaline (epinephrine) acid tartrate | Injection, solution | 1.82 mg/mL | Current | Limited Availability | Manufacturing | 9/12/2024 |
| pantoprazole sodium sesquihydrate | Injection, powder for | 45.12 mg | Discontinued | Unavailable | Manufacturing | 9/12/2024 |
| acetylcysteine | Injection, concentrated | 2 g | Current | Limited Availability | Transport / Logistic issues / Storage capacity issues | 9/12/2024 |
| tobramycin | Injection, solution | 40 mg/mL | Current | Limited Availability | Unexpected increase in consumer demand | 9/12/2024 |
| noradrenaline (norepinephrine) acid tartrate monohydrate | Injection, concentrated | 2 mg/mL | Resolved | Available | Transport / Logistic issues / Storage capacity issues | 9/12/2024 |
| adrenaline (epinephrine) acid tartrate | Injection, solution | 1.819 mg | Resolved | Available | Unexpected increase in demand due to other sponsors unable to supply | 9/12/2024 |
| hydromorphone hydrochloride | Injection, solution | 2 mg | Resolved | Available | Manufacturing | 9/12/2024 |
| Fremanezumab | Injection, solution | 225 mg | Anticipated | Available | Unexpected increase in consumer demand | 9/12/2024 |
| sodium amidotrizoate~amidotrizoate meglumine | Injection, intravenous infusion | 40 mg/mL~260 mg/mL | Resolved | Available | Manufacturing | 9/12/2024 |
| clarithromycin | Oral Liquid, powder for | 50 mg/mL | Resolved | Available | Unexpected increase in consumer demand | 9/12/2024 |
2024年12月16日